Raffaele Colombo: Honored to be named one of the 2024 PharmaVoice 100

Raffaele Colombo shared about being named one of the 2024 PharmaVoice 100. Read his post on LinkedIn below:

“It’s an incredible honor and privilege to be named one of the 2024 PharmaVoice 100 by PharmaVoice, alongside so many talented and inspiring leaders in the life sciences industry!

Each winner represents the transformative impact of the pharmaceutical industry in their own unique way and this recognition reflects our collective dedication and passion for advancing healthcare innovation.

Check out the full list of the this year PharmaVoice 100 honorees here.

Thanks to the fantastic mentors, collegues, and friends who have guided, inspired, supported, and helped me along the way—there are way too many to name! I’m excited for what we’ll continue to achieve together.”

Zymeworks Inc. congratulated Raffaele:

“We are thrilled to share that Raffaele Colombo, PhD, our Associate Director, Medicinal Chemistry, has been selected as a 2024 PharmaVoice 100 honoree!

With over 15 years of experience working in academia, pharma, and biotech, focusing on the research, design, and synthesis of new payloads and drug-linkers for antibody-drug conjugates (ADCs), Dr. Colombo has been instrumental in advancing our company’s pipeline, notably leading the development of novel ADC candidates designed to balance efficacy and tolerability.

Dr. Colombo’s leadership extends well beyond the lab, earning him recognition as a sought-after collaborator and speaker at major industry conferences. His contributions to Zymeworks and the ADC field have strengthened our position as a leader in multifunctional drug development, while inspiring the next generation of scientists in the life sciences.

We’re proud to have Dr. Colombo as a key member of our team, whose dedication and expertise continue to push boundaries and shape the future of cancer research.

Learn more.”

More posts featuring Raffaele Colombo.

Raffaele Colombo, a leading figure in the pharmaceutical industry is the Associate Director of Medicinal Chemistry at Zymeworks Inc.. His leadership and scientific acumen drive the discovery and optimization of novel drug candidates and advancing the treatment landscape for various diseases.